The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey confirms psoriasis and psoriatic arthritis (PsA) are frequently under treated or not treated at all. MAPP is the first probability survey that looked at patients, regardless of whether they were under the care of a healthcare provider or member of a patient advocacy group, and also included the physician perspective. The survey interviewed 3,426 patients who were randomly selected via a telephone survey of 139,948 households in the United States, Canada, France, Germany, Italy, Spain, and the United Kingdom. It also interviewed a total of 781 physicians from North America and Europe. The survey explored the following:
- Impact of psoriasis and PsA on disease-related quality of life (QoL)
- Physician-patient relationship
- Unmet treatment need
- Patients' satisfaction with current medical care and therapies
Lead investigator Mark G. Lebwohl, MD, The Mount Sinai Medical Centre, said: "For decades, healthcare providers have been searching for ways to help these psoriasis and psoriatic arthritis patients live more productive lives in spite of their diseases. The MAPP survey allows us to gain a deeper understanding of the gap between what current assessment tools indicate disease impact should be, versus what the patients are experiencing - and based on the survey - there appears to be a large gap."
Below are some key findings from the MAPP survey:
- 85% of patients stated that there was a need for better therapies
- 60% of PsA patients said they were not receiving any treatment
- Psoriasis patients with 4% or more of their body surface area (BSA) covered by psoriasis were receiving no treatment or only topical therapy
- 57% of patients who were prescribed traditional oral medication stopped using it
- 45% of patients who were prescribed a biologic stopped using it
- Safety and tolerability issues or lack/loss of efficacy were most common reasons for treatment discontinuation
- Half of the patients surveyed indicated that both traditional oral medication and biologics were burdensome
- Patients had anxiety/fear of injection and physical preparation for self-injection
- PsA patients with more than 4 affected joints had difficulty or were unable to do ordinary daily tasks such as bending down, dressing themselves, getting in and out of bed/car, and washing/drying their body
According to Randy Beranek, president and CEO of the National Psoriasis Foundation, there is a disconnect between the way patients and physicians define severity. Beranek noted: "Determining the severity of psoriasis and psoriatic arthritis is difficult because health care providers often focus on elements that are easily measured, such as the size of the psoriasis lesions or the number of joints affected. However, severity should also include impact on quality of life. For instance, someone with psoriasis on a small surface area such as their hands and feet will find it can have a significant effect on their daily activities. Even a small number of affected joints can cause significant pain and impact mobility with psoriatic arthritis."
To read more about the findings from the survey, please visit here.